This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Compounds~~ A compound of ~~the general~~ formula ~~(I):~~ (I)



(I)

~~in which:~~ wherein

X = ~~O or~~ is S;

R1 is ~~chosen from:~~

-Alk-COOH,

-Alk-C(=O)-$(O)_m$-Ar,

-Alk-C(=O)-$(O)_m$-Het,

-Alk-C(=O)-$(O)_m$-Alk,

-Alk-C(=O)-$(O)_m$-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-$(O)_m$-Ar,

-Alk-O-Alk,

-Alk-O-Alk-Ar, or

-Alk-O-Het;

R2 is ~~chosen from~~ -OH, -OAlk, -NR7R8, -OAr, -OHet ~~and~~ or -O-cycloalkyl;

R7 is ~~chosen from~~ H ~~and~~ or -Alk;

R8 is ~~chosen from~~

-H;

-Alk' or -cycloalkyl,

~~in~~ which Alk' or cycloalkyl is optionally substituted by one or more ~~groups chosen from~~ of -OAlk, -CN, -OHet, -OH, -C(=O)-$(O)_m$Alk, -C(=O)-$(O)_m$Ar, -C(=O)-$(O)_m$Het, -C(=O)-

$(O)_m$-cycloalkyl, -COOH ~~and~~ or $-NO_2$;

-Ar' or Het',

~~in~~ which Ar' or Het' is optionally substituted by one or more ~~groups chosen from~~ of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, $-CF_3$, -AlkAr, -COOH -NRR', -Het, $-C(=O)-(O)_mAlk$, $-C(=O)-(O)_mAr$, $-C(=O)-(O)_mHet$, $-C(=O)-(O)_m$-cycloalkyl ~~and~~ or NO_2;

or R7 and R8 form, together with the nitrogen atom to which they are attached, a nitrogenous heterocycle of 5 to 10 atoms;

R3, R4, R5 and R6, which may be identical or different, are ~~chosen~~ each independently, ~~from~~ H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' ~~and~~ or $-NO_2$;

~~in which, in the definitions of R1-R8:~~

~~each of the~~ Alk, each of which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN,-OAr, $-CF_3$, -COOH, -NRR', $-C(=O)-(O)_mAlk$, -Het ~~and~~ or $-NO_2$;

~~each of the~~ Ar, each of which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, $-CF_3$, -AlkAr, -COOH, $-C(=O)-(O)_mAlk$, $-Alk-C(=O)-(O)_mAlk$, -NRR', -Het, $-NO_2$, $-S(O)_n$-Ar ~~and~~ or $-S(O)_nAlk$;

R and R' are, each ~~chosen~~ independently, ~~from~~ H ~~and~~ or Alk;

m = ~~0~~ is 0 or 1;

n = ~~0~~ is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;

Ar and Ar' are, each independently, an aryl radical;

Het and Het' are, each independently, a heteroaryl radical; and

Hal is a halogen radical;

~~and also the stereoisomers thereof, and the racemates and~~ or a pharmaceutically acceptable ~~salts~~ salt thereof,

with the exception of the compounds for which :

1) R1 = CH_2-phenyl, optionally substituted by $-NO_2$ or -OMe,
R2 = -OMe, -OEt or -OH,
R3, and R6 = H,

R4, and R5 = H or -OMe, and

X = ~~O or~~ S; ~~, or~~

2) R1 = $-CH_2-C(=O)Me$,

R3, R4, R5, and R6 = H, ~~X = O and R2 = -OEt or~~

X = S, and

R2 = -OMe;

3) ~~R1 = $-CH_2-CO_2Et$, R2 = -OEt, R3, R4, R6 = H, X = O and R5 = $-NH_2$ or $-NO_2$; or~~

R1 = $-CH_2-CO_2Me$,

R3, R4, R5, and R6 = H,

R2 = -OMe or -OH, ~~and X = O or S, or R2 = -OH~~ and

X = S; ~~or~~

and

R1 = $-CH_2CO_2H$,

R3, R4, R5, and R6 = H,

R2 = OH, and

X = S;

and

4) R1 = $-CH_2$-phenyl,

$R2 = -NH_2$,

X = ~~O,~~ S, and

R5 = -OMe~~, or X = O and R5 = phenyl~~.

2. (Currently Amended) ~~Compounds~~ A compound of ~~the general formula (I)~~ according to Claim 1, ~~in which:~~ wherein

~~R2 =~~ R2 is ~~-~~Oet; ~~and X = S, and~~

R1 is ~~chosen from:~~

-Alk-COOH,

$-Alk-C(=O)-(O)_m-Ar$,

-Alk-C(=O)-$(O)_m$-Het,

-Alk-C(=O)-$(O)_m$-Alk,

-Alk-C(=O)-$(O)_m$-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-$(O)_m$-Ar,

-Alk-O-Alk,

-Alk-O-Alk-Ar, or

-Alk-O-Het; [[,]]

R3, R4, R5 and R6, which may be identical or different, are ~~chosen~~ each independently, ~~from~~ H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' ~~and~~ or $-NO_2$;

~~in which, in the definitions of R1-R8:~~

~~each of the~~ Alk, each of which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN,-OAr, $-CF_3$, -COOH, -NRR', -C(=O)-$(O)_m$Alk, -Het ~~and~~ or $-NO_2$;

~~in which each of the~~ Ar, each which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, $-CF_3$, -AlkAr, -COOH, -C(=O)-$(O)_m$Alk, -Alk-C(=O)-$(O)_m$Alk, -NRR', -Het, $-NO_2$, -S$(O)_n$-Ar ~~and~~ or -S$(O)_n$Alk;

R and R' are, each ~~chosen~~ independently, ~~from~~ H ~~and~~ or Alk;

~~m =~~ m is 0 or 1;

~~n =~~ n is 0, 1 or 2 [[;]]

~~and also the stereoisomers thereof, and the racemates and pharmaceutically acceptable salts thereof~~.

3. (Currently Amended) ~~Compounds of the general formula (I)~~ A compound according to Claim 1, in ~~which:~~ which

~~X = O or S;~~

R1 is ~~chosen from:~~

-Alk-COOH,

-Alk-C(=O)-$(O)_m$-Ar,

-Alk-C(=O)-$(O)_m$-Het,

-Alk-C(=O)-$(O)_m$-Alk,

-Alk-C(=O)-$(O)_m$-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-$(O)_m$-Ar,

-Alk-O-Alk,

-Alk-O-Alk-Ar, or

-Alk-O-Het;

~~R2 =~~ R2 is -NR7R8 in which

R7 is ~~chosen from~~ H ~~and~~ or -Alk;

R8 is ~~chosen from~~

-Alk' or -cycloalkyl,

~~in~~ which Alk' or cycloalkyl is optionally substituted by one or more ~~groups chosen from~~ of -OAlk, -CN, -OHet, -OH, -C(=O)-$(O)_m$Alk, -C(=O)-$(O)_m$Ar, -C(=O)-$(O)_m$Het, -C(=O)-$(O)_m$cycloalkyl, -COOH ~~and~~ or -NO_2;

-Ar' or Het';

~~in~~ which Ar' or Het' is optionally substituted by one or more ~~groups chosen from~~ of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -AlkAr, -COOH -NRR', -Het, -C(=O)-$(O)_m$Alk, -C(=O)-$(O)_m$Ar, -C(=O)-$(O)_m$Het, -C(=O)-$(O)_m$cycloalkyl ~~and~~ or NO_2;

R3, R4, R5 and R6, which may be identical or different, are ~~chosen~~ each independently, ~~from~~ H, -Hal, -OH, -Alk, -OAlk, -CN, -CF_3, -NRR' ~~and~~ or -NO_2;

~~in which each of the~~ Alk, each of which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -COOH, -NRR', -C(=O)-$(O)_m$Alk, -Het ~~and~~ or -NO_2;

~~in which each of the~~ Ar, each of which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF_3, -AlkAr, -COOH, -C(=O)-$(O)_m$Alk, -Alk-C(=O)-$(O)_m$Alk, -NRR', -Het, -NO_2, -S$(O)_n$-Ar ~~and~~ or -S$(O)_n$Alk;

R and R' are, each ~~chosen~~ independently, ~~from~~ H ~~and~~ or Alk;

~~m =~~ m is 0 or 1;

~~n =~~ n is 0, 1 or 2~~;~~

~~X = O or~~ is ~~S;~~

~~R1 is chosen from:~~

~~-Alk-COOH,~~

~~-Alk-C(=O)-(O)$_m$-Ar,~~

~~-Alk-C(=O)-(O)$_m$-Het,~~

~~-Alk-C(=O)-(O)$_m$-Alk,~~

~~-Alk-C(=O)-(O)$_m$-cycloalkyl,~~

~~-Alk-C(=O)NRR',~~

~~-Alk-(O)$_m$-Ar,~~

~~-Alk-O-Alk,~~

~~-Alk-O-Alk-Ar,~~

~~-Alk-O-Het;~~

~~and also the stereoisomers thereof, and the racemates and pharmaceutically acceptable salts thereof,~~.

4. (Currently Amended) ~~Compounds~~ A compound ~~of the formula (I)~~ according to Claim 1, in which R3, R4, R5, and R6 ~~= H~~ are H.

5. (Cancelled)

6. (Currently Amended) ~~Compounds~~ A compound ~~of the formula (I)~~ according to Claim 1, in which ~~R2 =~~ R2 is -OAlk.

7. (Currently Amended) ~~Compounds~~ A compound ~~of the formula (I)~~ according to Claim 1, in which ~~m =~~ m is 0.

8. (Currently Amended) ~~Compounds~~ A compound ~~of the formula (I)~~ according to Claim 1, in which ~~R2 =~~ R2 is -NR7R8,

~~in which~~

~~R7 =~~ R7 is H or Alk, and

~~R8 =~~ R8 is -Alk' optionally substituted by -C(=O)-OAlk, -Het' or, -Ar' optionally substituted by -Hal, -C(=O)OAlk or -Alk-C(=O)OAlk.

9. (Currently Amended) ~~Compounds~~ A compound ~~of the formula (I)~~

according to Claim 1, in ~~which:~~ which

~~R1 =~~ R1 is -CH_2-COOH, -CH_2-C(=O)-$(O)_m$-Ar, -CH_2-C(=O)-$(O)_m$-Het, -CH_2-C(=O)-$(O)_m$-Alk, -CH_2-C(=O)NRR', -CH_2-$(O)_m$-Ar, -CH_2-O-Alk, -CH_2-O-Alk-Ar, or -CH_2-O-Het; ~~in which~~

Ar is optionally substituted by one or more ~~groups chosen from~~ of Hal, -OAlk, -Ar, -Alk, -O-Alk-Ar, -C(=O)-$(O)_m$-Alk, -Alk-C(=O)-$(O)_m$Alk, -S$(O)_n$-Ar, -S$(O)_n$-Alk, -O-CF_3, -CN ~~and~~ or -OH,

~~in which m =~~ m is 0 or 1, and ~~n =~~ n is 2.

10. (Currently Amended) ~~Compounds~~ A compound ~~of the formula (I)~~ according to Claim 1, in which ~~R1 =~~ R1 is -CH_2-C(=O)-Ar, -CH_2-C(=O)-Alk or -$(CH_2)_m$'-$(O)_m$-Ar, ~~in which~~

Ar is optionally substituted by one or more ~~groups chosen from~~ of Hal, -OAlk, -Ar, -Alk, -O-Alk-Ar, -C(=O)-$(O)_m$-Alk, -Alk-C(=O)-$(O)_m$Alk, -S$(O)_n$-Ar, -S$(O)_n$-Alk, -O-CF_3, -CN ~~and~~ or -OH,

~~in which m =~~ m is 0 or 1, ~~m' =~~ m' is 1 or 2, and ~~n =~~ n is 2.

11. (Currently Amended) ~~Compounds~~ A compound ~~of the formula (I)~~ according to Claim 10, in which ~~m' =~~ m' is 2 ~~if~~ and ~~m =~~ m is 1.

12. (Currently Amended) ~~Compounds~~ A compound ~~of the formula (I)~~ according to Claim 1, in which ~~Ar =~~ Ar is phenyl.

13. (Currently Amended) ~~Compounds~~ A compound ~~of the formula (I)~~ according to Claim 1, in which ~~R1 =~~ R1 is -CH_2-C(=O) Alk.

14. (Currently Amended) ~~Compounds~~ A compound ~~of the formula (I)~~ according to Claim 13, in which ~~Alk =~~ Alk is -CMe_3.

15. (Currently Amended) ~~Compounds~~ A compound ~~of the formula (I)~~ according to Claim 1, in which ~~R1 =~~ R1 is -CH_2-C(=O)-phenyl or -CH_2-phenyl, in which phenyl is optionally substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk ~~and~~ or

-CN.

16. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~chosen from:~~ which is

ethyl 3-[2-(4-chlorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(2-oxo-2-phenylethoxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(2-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(2-biphenyl-4-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(2-oxo-2-*p*-tolylethoxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(2-adamantan-1-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(4-fluorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(3-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(4-benzyloxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(1-methyl-2-oxo-2-phenylethoxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(2,4-dimethoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(3,3-dimethyl-2-oxobutoxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(2-naphthalen-2-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(2,3-dichloro-4-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(2-benzyloxy-5-fluorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-hydroxybenzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(4-fluorophenoxy)ethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-phenethyloxybenzo[*b*]thiophene-2-carboxylate;

ethyl 3-(2-phenoxyethoxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(4-cyanophenoxy)ethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-{2-[4-(2-methoxycarbonylethyl)phenoxy]ethoxy}benzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(naphthalen-1-yloxy)ethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(2-methoxyphenoxy)ethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-[2-(2,3-dimethylphenoxy)ethoxy]benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(2'-cyanobiphenyl-4-ylmethoxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(2-hydroxy-3-phenoxypropoxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(3-phenoxypropoxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(2-cyanobenzyloxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(3-cyanobenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-cyanobenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(2-benzenesulfonylmethylbenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-methoxycarbonylbenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-trifluoromethoxybenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-pentafluorophenylmethoxybenzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(naphthalen-2-ylmethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(biphenyl-2-ylmethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(3-methoxybenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-fluorobenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-bromobenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-methylbenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-benzyloxybenzo[*b*]thiophene-2-carboxylate; or
ethyl 3-(2,3-difluorobenzyloxy)benzo[*b*]thiophene-2-carboxylate;
~~and also the stereoisomeric forms, and the racemates and~~ or a pharmaceutically acceptable ~~salts~~ salt thereof.

17. (Currently Amended) ~~Process~~ A process for ~~the preparation~~ preparing of a compound ~~of the formula (I)~~ according to Claim 1, comprising ~~the step consisting in using:~~ reacting
a compound of ~~the~~ formula (IV)



(IV)

with a ~~halo derivative of the~~ compound of formula ~~(V):~~ (V)
Hal-R1 (V)
~~in which~~ wherein R1-R6 and X are defined as ~~in any one of the preceding claims, with an equimolar amount,~~ for the compounds of formula (I), in a polar solvent, at a temperature of

~~from~~ -20 to 200°C.

18. (Currently Amended) ~~Process for the preparation of the compounds of the formula (I), for which the compound of the formula (IV) is obtained by adding~~ A process for preparing a compound according to claim 1, comprising reacting a compound of ~~the~~ formula ~~(II):~~ (II)



(II)

~~in which~~ wherein R3-R6 and X are as defined ~~in Claim 1~~ for the compounds of formula (I), and R represents a hydrogen atom or an alkyl radical, ~~to~~

with a ~~2-haloethanone derivative of the~~ compound of formula ~~(III):~~ (III)



(III)

~~in which~~ wherein Hal represents a halogen atom and R2 is as defined ~~in any one of Claims 1 to 16~~ for the compounds of formula (I), in a polar solvent, at a temperature of ~~from~~ -20 to 200°C, followed by cyclization in a polar solvent, at a temperature of ~~from~~ -20 to 200°C.

19. (Currently Amended) ~~Process for the preparation of the compounds of the formula (I)~~ A process according to Claim 17, ~~for which the said~~ wherein the polar solvent is ~~chosen from:~~ ethanol, methanol, water, DMF, NMP, DMSO ~~and~~ or iPrOH.

20. (Currently Amended) ~~Pharmaceutical compositions~~ A pharmaceutical composition comprising ~~the compounds of the~~ a pharmaceutically acceptable carrier and a compound of formula ~~(I):~~ (I)



(I)

in ~~which:~~ which

X = ~~O or~~ is S;

R1 is ~~chosen from:~~

-Alk-COOH,

-Alk-C(=O)-$(O)_m$-Ar,

-Alk-C(=O)-$(O)_m$-Het,

-Alk-C(=O)-$(O)_m$-Alk,

-Alk-C(=O)-$(O)_m$-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-$(O)_m$-Ar,

-Alk-O-Alk, or

-Alk-O-Alk-Ar, or

-Alk-O-Het;

R2 is ~~chosen from~~ -OH, -OAlk, -NR7R8, -OAr, -OHet ~~and~~ or -O-cycloalkyl;

R7 is ~~chosen from~~ H ~~and~~ or -Alk;

R8 is ~~chosen from~~

-H;

-Alk' or -cycloalkyl,

~~in~~ which Alk' or cycloalkyl is optionally substituted by one or more ~~groups chosen from~~ of -OAlk, -CN, -OHet, -OH, -C(=O)-$(O)_m$Alk, -C(=O)-$(O)_m$Ar, -C(=O)-$(O)_m$Het, -C(=O)-$(O)_m$-cycloalkyl, -COOH ~~and~~ or -NO_2;

-Ar' or Het',

~~in~~ which Ar' or Het' is optionally substituted by one or more ~~groups chosen from~~ of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -AlkAr, -COOH -NRR', -Het, -C(=O)-$(O)_m$Alk, -C(=O)-$(O)_m$Ar, -C(=O)-$(O)_m$Het, -C(=O)-$(O)_m$-cycloalkyl ~~and~~ or NO_2;

or R7 and R8 form, together with the nitrogen atom to which they are attached, a nitrogenous heterocycle of 5 to 10 atoms;

R3, R4, R5 and R6, which may be identical or different, are ~~chosen~~ each independently, ~~from~~ H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' ~~and~~ or $-NO_2$;

~~in which, in the definitions of R1-R8:~~

~~each of the~~ Alk, each of which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN,-OAr, $-CF_3$, -COOH, -NRR', $-C(=O)-(O)_mAlk$, -Het ~~and~~ or $-NO_2$;

~~each of the~~ Ar, each of which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, $-CF_3$, -AlkAr, -COOH, $-C(=O)-(O)_mAlk$, $-Alk-C(=O)-(O)_mAlk$, -NRR', -Het, $-NO_2$, $-S(O)_n-Ar$ ~~and~~ or $-S(O)_nAlk$;

R and R' are, ~~chosen~~ independently, ~~from~~ H ~~and~~ or Alk;

~~m =~~ m is 0 or 1;

~~n =~~ n is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;

Ar and Ar' are, each independently, an aryl radical;

Het and Het' are, each independently, a heteroaryl radical; and

Hal is a halogen radical;

~~and also the stereoisomers thereof, and the racemates and~~ or a pharmaceutically acceptable ~~salts~~ salt thereof.

21. (Currently Amended) ~~Pharmaceutical compositions,~~ A pharmaceutical composition, ~~in which X and R1-R6 are as defined according to~~ comprising a pharmaceutically acceptable carrier and a compound of claim 2.

22. (Currently Amended) ~~Use of the compounds of the~~ A method for reducing hyperglycaemia, comprising administering to a subject in need thereof an effective amount of a compound of formula ~~(I):~~ (I)



(I)

~~in which:~~ wherein

X ~~= O or~~ is S;

R1 is ~~chosen from:~~

-Alk-COOH,

-Alk-C(=O)-$(O)_m$-Ar,

-Alk-C(=O)-$(O)_m$-Het,

-Alk-C(=O)-$(O)_m$-Alk,

-Alk-C(=O)-$(O)_m$-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-$(O)_m$-Ar,

-Alk-O-Alk,

-Alk-O-Alk-Ar, or

-Alk-O-Het;

R2 is ~~chosen from~~ -OH, -OAlk, -NR7R8, -OAr, -OHet ~~and~~ or -O-cycloalkyl;

R7 is ~~chosen from~~ H ~~and~~ or -Alk;

R8 is ~~chosen from~~

-H;

-Alk' or -cycloalkyl,

~~in~~ which Alk' or cycloalkyl is optionally substituted by one or more ~~groups chosen from~~ of -OAlk, -CN, -OHet, -OH, -C(=O)-$(O)_m$Alk, -C(=O)-$(O)_m$Ar, -C(=O)-$(O)_m$Het, -C(=O)-$(O)_m$-cycloalkyl, -COOH ~~and~~ or -NO_2;

-Ar' or Het',

~~in~~ which Ar' or Het' is optionally substituted by one or more ~~groups chosen from~~ of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -AlkAr, -COOH -NRR', -Het, -C(=O)-$(O)_m$Alk, -C(=O)-$(O)_m$Ar, -C(=O)-$(O)_m$Het, -C(=O)-$(O)_m$-cycloalkyl ~~and~~ or NO_2;

or R7 and R8 form, together with the nitrogen atom to which they are attached, a

nitrogenous heterocycle of 5 to 10 atoms;

R3, R4, R5 and R6, which may be identical or different, are ~~chosen~~ each independently, ~~from~~ H, -Hal, -OH, -Alk, -OAlk, -CN, -CF_3, -NRR' ~~and~~ or -NO_2;

~~in which, in the definitions of R1-R8:~~

~~each of the~~ Alk, each of which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -COOH, -NRR', -C(=O)-$(O)_m$Alk, -Het ~~and~~ or -NO_2;

~~each of the~~ Ar, each of which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -AlkAr, -COOH, -C(=O)-$(O)_m$Alk, -Alk-C(=O)-$(O)_m$Alk, -NRR', -Het, -NO_2, -$S(O)_n$-Ar ~~and~~ or -$S(O)_n$Alk;

R and R' are, ~~chosen~~ each independently, ~~from~~ H ~~and~~ or Alk;

~~m =~~ m is 0 or 1;

~~n =~~ n is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;

Ar and Ar' are, each independently, an aryl radical;

Het and Het' are, each independently, a heteroaryl radical; and

Hal is a halogen radical;

~~and also the stereoisomers thereof, and the racemates and~~ or a pharmaceutically acceptable ~~salts~~ salt thereof~~,~~

~~for the manufacture of a medicament for reducing hyperglycaemia.~~

23. (Currently Amended) ~~Use~~ A method according to Claim 22, ~~for which the said medicament is for the treatment of~~ wherein diabetes is treated.

24. (Currently Amended) ~~Utilisation~~ A method according to Claim 22, ~~for which the said medicament is for the treatment of~~ wherein non-insulin-dependent diabetes is treated.

25. (Currently Amended) ~~Use~~ A method according to Claim 22, ~~for which~~

~~the said medicament is for the treatment of~~ wherein dyslipidaemia and/or obesity is treated.

26. (Currently Amended) ~~Use~~ A method according to Claim 22, ~~for which the said medicament is for the treatment of and/or preventing~~ wherein a diabetes-related microvascular ~~and~~ or macrovascular ~~complications~~ complication is treated or prevented.

27. (Currently Amended) ~~Use~~ A method according to Claim 26, ~~for which the said~~ wherein the microvascular ~~and~~ or macrovascular ~~complications are chosen from~~ complication is atherosclerosis, arterial hypertension, a diabetes-related inflammatory ~~processes~~ process, microangiopathy, macroangiopathy, retinopathy ~~and~~ or neuropathy.

28. (Cancelled)

29. (New) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 1.

30. (New) A method for reducing hyperglycaemia, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

31. (New) A compound of claim 1, wherein

R1 is

-Alk-COOH,

-Alk-C(=O)-$(O)_m$-Ar,

-Alk-C(=O)-$(O)_m$-Alk,

-Alk-C(=O)-$(O)_m$-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-$(O)_m$-Ar,

-Alk-O-Alk, or

-Alk-O-Alk-Ar;

R2 is -OH, -OAlk, -NR7R8, -OAr, or -O-cycloalkyl;

R7 is H or -Alk;

R8 is

-H;

-Alk' or -cycloalkyl,

which Alk' or cycloalkyl is optionally substituted by one or more of -OAlk, -CN, -OH, -$C(=O)$-$(O)_m$Alk, -$C(=O)$-$(O)_m$Ar, -$C(=O)$-$(O)_m$-cycloalkyl, -COOH or -NO_2;

-Ar',

which Ar' is optionally substituted by one or more of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -AlkAr, -COOH -NRR', -$C(=O)$-$(O)_m$Alk, -$C(=O)$-$(O)_m$Ar, -$C(=O)$-$(O)_m$-cycloalkyl or NO_2;

R3, R4, R5 and R6, which may be identical or different, are each independently, H, -Hal, -OH, -Alk, -OAlk, -CN, -CF_3, -NRR' or -NO_2;

Alk, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -COOH, -NRR', -$C(=O)$-$(O)_m$Alk, or -NO_2;

Ar, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -AlkAr, -COOH, -$C(=O)$-$(O)_m$Alk, -Alk-$C(=O)$-$(O)_m$Alk, -NRR', -NO_2, -$S(O)_n$-Ar or -$S(O)_n$Alk;

R and R' are, each independently, H or Alk;

m is 0 or 1;

n is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;

Ar and Ar' are, each independently, an aryl radical; and

Hal is a halogen radical;

or a pharmaceutically acceptable salt thereof.

32. (New) A pharmaceutical composition of claim 20, wherein

X is S;

R1 is

-Alk-COOH,

-Alk-C(=O)-$(O)_m$-Ar,

-Alk-C(=O)-$(O)_m$-Alk,

-Alk-C(=O)-$(O)_m$-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-$(O)_m$-Ar,

-Alk-O-Alk, or

-Alk-O-Alk-Ar;

R2 is -OH, -OAlk, -NR7R8, -OAr, or -O-cycloalkyl;

R7 is H or -Alk;

R8 is

-H;

-Alk' or -cycloalkyl,

which Alk' or cycloalkyl is optionally substituted by one or more of -OAlk, -CN, -OH, -C(=O)-$(O)_m$Alk, -C(=O)-$(O)_m$Ar, -C(=O)-$(O)_m$-cycloalkyl, -COOH or -NO_2;

-Ar',

which Ar' is optionally substituted by one or more of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -AlkAr, -COOH -NRR', -C(=O)-$(O)_m$Alk, -C(=O)-$(O)_m$Ar, -C(=O)-$(O)_m$-cycloalkyl or NO_2;

R3, R4, R5 and R6, which may be identical or different, are each independently, H, -Hal, -OH, -Alk, -OAlk, -CN, -CF_3, -NRR' or -NO_2;

Alk, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -COOH, -NRR', -C(=O)-$(O)_m$Alk, or -NO_2;

Ar, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -AlkAr, -COOH, -C(=O)-$(O)_m$Alk, -Alk-C(=O)-$(O)_m$Alk, -NRR', -NO_2, -$S(O)_n$-Ar or -$S(O)_n$Alk;

R and R' are, independently, H or Alk;

m is 0 or 1;

n is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;

Ar and Ar' are, each independently, an aryl radical; and

Hal is a halogen radical;

or a pharmaceutically acceptable salt thereof.

33. (New) A method according to claim 22, wherein

X is S;

R1 is

-Alk-COOH,

-Alk-C(=O)-$(O)_m$-Ar,

-Alk-C(=O)-$(O)_m$-Alk,

-Alk-C(=O)-$(O)_m$-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-$(O)_m$-Ar,

-Alk-O-Alk, or

-Alk-O-Alk-Ar;

R2 is -OH, -OAlk, -NR7R8, -OAr, or -O-cycloalkyl;

R7 is H or -Alk;

R8 is

-H;

-Alk' or -cycloalkyl,

which Alk' or cycloalkyl is optionally substituted by one or more of -OAlk, -CN, -OH, -C(=O)-$(O)_m$Alk, -C(=O)-$(O)_m$Ar, -C(=O)-$(O)_m$-cycloalkyl, -COOH or -NO_2;

-Ar',

which Ar' is optionally substituted by one or more of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, -CF_3, -AlkAr, -COOH -NRR', -C(=O)-$(O)_m$Alk, -C(=O)-$(O)_m$Ar, -C(=O)-$(O)_m$-cycloalkyl or NO_2;

R3, R4, R5 and R6, which may be identical or different, are each independently, H, -Hal, -OH, -Alk, -OAlk, -CN, -CF_3, -NRR' or -NO_2;

Alk, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN,-OAr, $-CF_3$, -COOH, -NRR', $-C(=O)-(O)_mAlk$, or $-NO_2$;

Ar, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN,-OAr, $-CF_3$, -AlkAr, -COOH, $-C(=O)-(O)_mAlk$, $-Alk-C(=O)-(O)_mAlk$, -NRR', $-NO_2$, $-S(O)_n-Ar$ or $-S(O)_nAlk$;

R and R' are, each independently, H or Alk;

m is 0 or 1;

n is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;

Ar and Ar' are, each independently, an aryl radical; and

Hal is a halogen radical;

or a pharmaceutically acceptable salt thereof.